# Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis

> **NCT03035006** · PHASE1,PHASE2 · TERMINATED · sponsor: **Taiwan Liposome Company** · enrollment: 1 (actual)

## Conditions studied

- HepatoCellular Carcinoma
- Portal Vein Tumor Thrombosis

## Interventions

- **DRUG:** Lipotecan

## Key facts

- **NCT ID:** NCT03035006
- **Lead sponsor:** Taiwan Liposome Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-04-14
- **Primary completion:** 2018-10-31
- **Final completion:** 2018-10-31
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Current study design couldn't support futher development on this indication.
- **Last updated:** 2018-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03035006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03035006, "Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03035006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*